Allakos Inc (ALLK)

$1.44 0.01 (0.69%)

16:00 EDT ALLK Stock Quote Delayed 30 Minutes

ALLK Stock Earnings: Allakos Meets EPS for Q1 2024

By InvestorPlace Earnings May 9, 2024

ALLK stock results show that Allakos met analyst estimates for earnings per share the first quarter of 2024.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

3 Biotech Stocks to Dump Before They Go to Zero

More Articles

Volume:

Previous Close -

Market Cap 124.65M

PE Ratio -2.94

EPS -0.49

Volume (Avg. Vol.) 468,818

Day's Range $1.36 - $1.46

52-Week Range $0.98 - $5.64

Dividend & Yield N/A (N/A)

ALLK Stock Predictions, Articles, and Allakos Inc News

From InvestorPlace
From the Web

ALLK Stock Earnings: Allakos Misses EPS for Q4 2023

By InvestorPlace Earnings Mar 14, 2024

ALLK stock results show that Allakos missed analyst estimates for earnings per share the fourth quarter of 2023.

Why Is Allakos (ALLK) Stock Down 57% Today?

By William White, InvestorPlace Writer Jan 16, 2024

Allakos stock is falling hard on Tuesday as investors in ALLK react to two of the company's Phase 2 clinical trials failing.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Nov 9, 2023

It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday morning!

3 Healthcare Stocks to Sell Before They Die

By Larry Ramer, InvestorPlace Contributor Sep 30, 2022

Troubled healthcare companies will have much more difficulty surviving, so identifying healthcare stocks to sell is very important.

Why Is Allakos (ALLK) Stock Soaring 25% Today?

By Josh Enomoto, InvestorPlace Contributor Sep 19, 2022

Although Allakos recently raised about $150 million to supports its drug development, the move carries risks for ALLK stock.

5 Important Investing Lessons From Allakos’ Price Collapse

By Stavros Georgiadis, CFA, InvestorPlace Contributor Jan 24, 2022

ALLK stock is a gamble now even after falling about 85% off its 52-week high. Allakos' slide offers investors with a learning opportunity.

Allakos Is a Cautionary Tale of Biopharmaceutical Investing

By Alex Sirois, InvestorPlace Contributor Jan 12, 2022

ALLK stock dropped off a cliff following disappointing study results, which illustrates what can go wrong in risky biopharma equities.

After a Clinical-Data Bombshell, Allakos Might Actually Be a Buy

By David Moadel, InvestorPlace Contributor Jan 5, 2022

After a well-publicized clinical-data letdown, it may be time to go long as the worst-case scenario has already been priced into ALLK stock.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Dec 23, 2021

Good morning, trader! Christmas is almost here but were aren't slowing down as we dive into the biggest pre-market stock movers for Thursday!

ALLK Stock Alert: Why Is Allakos Absolutely Plunging Today?

By Samuel O'Brient, InvestorPlace Reporter Dec 22, 2021

Allakos' recent study results have sent ALLK stock straight to the bottom. Here's what investors should know right now.

7 of the Best Pharma Stocks to Buy Now

By Louis Navellier and the InvestorPlace Research Staff May 11, 2021

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year.

Allakos stock falls as analysts downgrade (NASDAQ:ALLK)

From Seeking Alpha Jan 17, 2024

Allakos (ALLK) stock faced downgrades as Wall Street reacted to Phase 2 setbacks for its lead asset lirentelimab that led to massive layoffs. Read more here.

Allakos crashes on restructuring plans (NASDAQ:ALLK)

From Seeking Alpha Jan 16, 2024

Allakos (ALLK) stock plummeted 61% after announcing plans to cut its workforce by 50% and focus on specific programs to extend its cash runway. Read more here.

Allakos files to sell up to $250M worth of its common stock (NASDAQ:ALLK)

From Seeking Alpha Nov 13, 2023

Allakos filed a prospectus for the sale of its common shares, totaling up to $250M.

Allokos stock jumps 16% as JMP starts coverage at market outperform (ALLK)

From Seeking Alpha Sep 27, 2023

JMP initiates coverage of Allakos (ALLK) with a market outperform rating, citing the market potential of its lead drug lirentelimab.

Why Shares of Allakos Are Up Wednesday

From The Motley Fool Sep 27, 2023

The stock is bouncing back from a recent 52-week low.

Why Allakos Stock Skyrocketed Nearly 9% Higher Today

From The Motley Fool May 12, 2023

The company is poised to report a critical set of clinical data in the coming months.

ADVERTISEMENT